Gynecological Endocrinology[JOURNAL]
Sun
200 papers
Beyond pain: employment status affects endometriosis-associated quality of life - a cross-sectional study.
Vibert J, Ben Jazia I, Alec M … +2 more , Benagiano G, Pluchino N
Gynecol Endocrinol · 2025 Dec · PMID 40552705 · Publisher ↗
: Endometriosis is a chronic condition affecting physical health, emotional well-being, and socioeconomic stability. While pain is a well-recognized determinant of health-related quality of life (HR-QoL), the role of pai...
: Endometriosis is a chronic condition affecting physical health, emotional well-being, and socioeconomic stability. While pain is a well-recognized determinant of health-related quality of life (HR-QoL), the role of pain experience over employment status remains underexplored. : To determine among women with endometriosis whether employment status independently contributes to HR-QoL, beyond clinical symptoms. This cross-sectional study was conducted at the University Hospital of Geneva. Women with a confirmed diagnosis of endometriosis were included. Employment status was categorized as full-time employment (>80%), part-time employment (≤80%), voluntary unemployment, and involuntary unemployment. HR-QoL was measured using the Endometriosis Health Profile-30 (EHP-30). A total of 324 patients were included (mean age 32 ± 7.2 years); 78.2% had deep infiltrating endometriosis, and 34.5% reported prior surgery. Regarding employment, 63.2% were employed (51.5% full-time, 11.7% part-time), while 36.7% were unemployed, including 26.2% by choice. Full-time and part-time employment were linked to lower EHP-30 pain scores, with part-time employment showing a stronger association (β = -34.48, 95% CI: -58.00 to -10.88, = 0.006) than full-time employment (β = -20.57, 95% CI: -40.70 to -0.43, = 0.046). Unemployed women actively seeking work exhibited worse HR-QoL, particularly in social support (β = 34.95, 95% CI: 1.89 to 70.80, = 0.048) and overall HR-QoL burden (β = 168.27, 95% CI: 30.60 to 205.91, = 0.019). : Employment status is an independent predictor of HR-QoL in women with endometriosis. Beyond pain, professional identity and social integration play key roles in endometriosis burden.
Association between serum Klotho and all-cause mortality in postmenopausal women: a prospective population-based cohort analysis from NHANES 2007-2016.
Zhang B, Zhang Y, Wang T … +1 more , Gao X
Gynecol Endocrinol · 2025 Dec · PMID 40511875 · Publisher ↗
This study investigated the association between serum Klotho levels and all-cause mortality in postmenopausal women. Utilizing data from 3,448 postmenopausal women in the US National Health and Nutrition Examination Surv...
This study investigated the association between serum Klotho levels and all-cause mortality in postmenopausal women. Utilizing data from 3,448 postmenopausal women in the US National Health and Nutrition Examination Survey (NHANES) from 2007 to 2016, multivariable-adjusted weighted Cox proportional hazards models were employed. Over a median follow-up of 106 months, 449 deaths occurred. Compared to the second tertile (T 2, 707.3-936.5 pg/mL), the adjusted HRs for all-cause mortality were 1.44 (95% CI: 1.11-1.86, p=0.005) for the first tertile (T 1, <707.3 pg/mL) and 1.31 (95% CI: 0.94-1.83, p=0.112) for the third tertile (T 3, ≥936.5 pg/mL). The restricted cubic spline model revealed an L-shaped association between serum Klotho levels and all-cause mortality, with an inflection point at an ln-transformed Klotho level of 6.638 pg/mL. Our findings suggest an L-shaped relationship between ln-transformed serum Klotho levels and all-cause mortality in postmenopausal women. Further research is needed to validate these results and elucidate the underlying mechanisms. .
Thyroid nodules and thyroid cancer in pregnancy.
Medenica S, Arjunan D, Mladenovic V … +4 more , Zankovic N, Aksam S, Gluvic Z, Dutta P
Gynecol Endocrinol · 2025 Dec · PMID 40511591 · Publisher ↗
Thyroid gland size increases during pregnancy due to physiological changes. 2-3% of pregnancies, a thyroid nodule (TN) may either newly develop or an existing one may increase in size. Factors such as age, parity, and io...
Thyroid gland size increases during pregnancy due to physiological changes. 2-3% of pregnancies, a thyroid nodule (TN) may either newly develop or an existing one may increase in size. Factors such as age, parity, and iodine status can influence the development of TN. Surveillance of TN in pregnancy is essentially similar to that of the general population as it is contraindicated. Fine needle aspiration cytology (FNAC) can be delayed until after delivery unless malignancy is suspected. Surgery is reserved for severe cases, those with rapid growth, or those with suspicious features. Surgery is typically performed during the second trimester. Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer during pregnancy, which ranks second among cancers affecting pregnant women. Given the challenges involved, the prognosis is still favorable, have minimal impact on survival rates or recurrence. Treatment guidelines suggest regular monitoring of TSH and thyroid ultrasound (TUS), ensuring careful management of TC, especially in cases of aggressive.
Daidzein-rich isoflavone aglycones inhibit 17β-hydroxysteroid dehydrogenase 1 and increase estrogen sulfotransferase in endometriosis.
Tarumi Y, Takaoka O, Izumi Y … +8 more , Katayama A, Shimura K, Okimura H, Kataoka H, Ito F, Kusuki I, Kitawaki J, Mori T
Gynecol Endocrinol · 2025 Dec · PMID 40497318 · Publisher ↗
OBJECTIVE: Endometriosis is an estrogen-dependent disease wherein isoflavones interact with estrogen receptors. Daidzein-rich isoflavone aglycones (DRIAs) have been shown to inhibit cell proliferation and aromatase activ...
OBJECTIVE: Endometriosis is an estrogen-dependent disease wherein isoflavones interact with estrogen receptors. Daidzein-rich isoflavone aglycones (DRIAs) have been shown to inhibit cell proliferation and aromatase activity in vitro and in vivo. This study aims to investigate the effects of DRIAs on the enzymes involved in estrogen metabolism in endometriosis. STUDY DESIGN: Stromal cells isolated from ovarian endometriomas (OESCs) were cultured with DRIAs. Ovarian endometrioma (OE) specimens were obtained from patients who were treated with or without DRIAs. The gene expressions involved in estrogen metabolism and 17β-hydroxysteroid dehydrogenase (HSD17β) 1 activity were analyzed using RT-PCR and thin layer chromatography, respectively. RESULTS: HSD17β1 expression in OE specimens was evaluated using immunohistochemical staining. DRIA treatment significantly suppressed HSD17β1 expression and elevated estrogen sulfotransferase (EST) levels in OESCs; however, no differences were observed in HSD17β2, HSD17β7, HSD17β12, and steroid sulfatase (STS) levels. HSD17β1 enzyme activity was inhibited by DRIAs. Furthermore, immunohistochemical analysis confirmed that HSD17β1 expression was suppressed in the OE specimens of patients undergoing treatment with DRIAs. CONCLUSIONS: DRIA treatment could suppress abnormal estrogen production via EST stimulation as well as the inhibition of aromatase and HSD17β1 activities, suggesting therapeutic potential in endometriosis that needs to be confirmed by our ongoing clinical trial. ay.
Comparison of the effects of piezoelectric and calcium ionophore activation on fertilization and blastulation rates of sibling oocytes.
Göde F, Pala I, Yıldırım F … +1 more , Abdi Z
Gynecol Endocrinol · 2025 Dec · PMID 40488378 · Publisher ↗
To determine rates of fertilization, good-quality day 3 embryos, and blastocyst progression in sibling oocytes of the same patients undergoing piezo and calcium ionophore (CaI) activation. The retrospective cohort study...
To determine rates of fertilization, good-quality day 3 embryos, and blastocyst progression in sibling oocytes of the same patients undergoing piezo and calcium ionophore (CaI) activation. The retrospective cohort study included couples undergoing assisted reproductive treatment in 2023-2024 for primary infertility with a history of low fertilization rates (<30%), low blastulation rates (<20%), or male factor infertility such as teratozoospermia at the Izmir University of Economics Medical Point Hospital IVF Center. Sibling oocytes from each patient were randomly assigned to piezoelectric or CaI activation. The fertilization rate, number of degenerated embryos, number of abnormally fertilized eggs, number of day 3 grade 1 embryos, and blastocyst counts were compared among the sibling oocytes. In total, 1,105 MII sibling oocytes from 76 patients were included. Piezoelectric activation was applied to 575 MII oocytes, while CaI activation was applied to 530 MII oocytes. There was no significant difference between groups according to the activation method in the fertilization rate (piezo, 0.74% ± 0.22%; CaI, 0.68% ± 0.26%, = 0.12), degeneration rate (piezo, 0.04% ± 0.13%; CaI, 0.02% ± 0.06%, = 0.452), day 3 grade 1 embryo rate (piezo, 0.59% ± 0.33%; CaI, 0.54% ± 0.35%, = 0.34), or blastocyst rate (piezo, 0.49% ± 0.33%; CaI, 0.43% ± 0.34%, = 0.28) of sibling oocytes. Both piezoelectric and CaI activation yielded comparable results in terms of oocyte activation, with similar fertilization and blastulation rates.
Adding human chorionic gonadotropin to frozen-thawed embryo transfer cycles pretreated with GnRH-a improves clinical pregnancy rates: a retrospective study.
Peng L, Wang Q, Chen Y … +1 more , Sun X
Gynecol Endocrinol · 2025 Dec · PMID 40481812 · Publisher ↗
This study evaluated whether intramuscular human chorionic gonadotropin (HCG) administration before endometrial transformation improves outcomes in frozen-thawed embryo transfer (FET) cycles pretreated with gonadotrophin...
This study evaluated whether intramuscular human chorionic gonadotropin (HCG) administration before endometrial transformation improves outcomes in frozen-thawed embryo transfer (FET) cycles pretreated with gonadotrophin-releasing hormone agonist (GnRH-a). We retrospectively analyzed 579 GnRH-a down-regulated hormone replacement FET cycles. Patients were divided into an HCG group (n=299 cycles, received HCG) and a control group (n=280 cycles, no HCG).The HCG group demonstrated significantly higher clinical pregnancy rates (58.5% vs. 49.3%, p<0.05) and embryo implantation rates (53.0% vs. 42.2%, p<0.05) compared to controls. Subgroup analysis showed HCG significantly increased clinical pregnancy rates in blastocyst transfer cycles (63.7% vs. 52.8%, p<0.05) but not in cleavage-stage transfers (52.5% vs. 43.3%, p>0.05). Multivariate logistic regression, adjusting for confounders, identified HCG administration as an independent factor positively associated with clinical pregnancy (OR = 1.751, 95% CI = 1.227-2.500, p=0.002).Administering intramuscular HCG before endometrial transformation in FET cycles pretreated with GnRH-a may improve clinical pregnancy rate and embryo implantation rate.
SIRT5 regulates granulosa cell proliferation and apoptosis in polycystic ovarian syndrome desuccinylation of GLI1.
Zhang Y, He F, Cai N … +4 more , Chen G, Wang Y, Bai W, Guo P
Gynecol Endocrinol · 2025 Dec · PMID 40481676 · Publisher ↗
Polycystic ovarian syndrome (PCOS) is a major cause of infertility. Succinylation is involved in disease processes; however, its role in PCOS remains unknown. This study aimed to analyze the effect of desuccinylase SIRT5...
Polycystic ovarian syndrome (PCOS) is a major cause of infertility. Succinylation is involved in disease processes; however, its role in PCOS remains unknown. This study aimed to analyze the effect of desuccinylase SIRT5 on granulosa cell phenotype and the molecular mechanism. The levels of succinylation-related enzymes were measured using reverse transcription-quantitative polymerase chain reaction and immunoblotting. Cell proliferation was evaluated using MTT and colony formation assays, and apoptosis was assessed using flow cytometry. The succinylation was analyzed using immunoprecipitation, cycloheximide chase assay, and immunoblotting. The results showed that SIRT5 was highly expressed in PCOS, and knockdown of SIRT5 promoted granulosa cell proliferation and inhibited apoptosis, as well as activated the SHH pathway. Moreover, silencing of SIRT5 promoted GLI1 succinylation at lysine (K)232 site and thereby suppressed its degradation. GLI1 knockdown reversed the promotion of proliferation and the inhibition of apoptosis caused by SIRT5 knockdown. Besides, SIRT5 knockdown attenuated ovarian dysfunction and inhibited apoptosis in PCOS rats by increasing GLI expression. In conclusion, silencing of SIRT5 facilitates granulosa cell proliferation and impedes apoptosis by succinylation of GLI1 at K232 site, and thus attenuates PCOS. The findings suggest that SIRT5 may be a promising target for PCOS therapy.
Factors associated with menopausal symptoms in southeast Chinese females aged 40-69 years.
Wang FX, Luo Z, Huang YZ … +9 more , Zhang Y, Ma LJ, Ding YH, Ning YM, Jiao J, Ying Q, Song PG, Xu L, Zhou JH
Gynecol Endocrinol · 2025 Dec · PMID 40476680 · Publisher ↗
This study aimed to investigate the prevalence, severity, and associated factors of menopausal symptoms among middle-aged Chinese women. A multicenter, population-based cross-sectional study was conducted, involving 7,48...
This study aimed to investigate the prevalence, severity, and associated factors of menopausal symptoms among middle-aged Chinese women. A multicenter, population-based cross-sectional study was conducted, involving 7,485 women aged 40-69 years from Zhejiang Province, China. Data on demographic characteristics, socioeconomic status, and lifestyle factors were collected using a structured questionnaire. Menopausal symptoms were assessed using the modified Kupperman Menopausal Index (mKMI), and multinomial logistic regression models were employed to identify factors linked to menopausal syndrome. The participants had a mean age of 52.4 (±7.3) years, with 46.1% being nonmenopausal and 53.9% postmenopausal. The most common menopausal symptoms were sexual problems (43.6%), insomnia (33.1%), and fatigue (27.5%). Among nonmenopausal women, insomnia was the most prevalent symptom (26.9%), whereas postmenopausal women most frequently reported sexual problems (61.1%). Both the prevalence and severity of menopausal symptoms significantly increased from nonmenopausal to postmenopausal status ( < 0.001). Significant associations were found between menopausal syndrome and factors such as age, menopausal status, education level, residence, income, passive smoking, physical activity, and occupational toxic exposure ( < 0.05). In conclusion, Sexual problems are the most bothersome menopausal symptom among females in southeast China. Postmenopausal females experience more prevalent and more severe symptoms. Additionally, socioeconomic and lifestyle factors play a significant role in menopausal syndrome.
Dissecting the causal effects of interleukin receptor-related factors and the risk of developing endometriosis: a two-sample Mendelian randomization study.
Lv SJ, Yuan Q, Zong SS … +1 more , Ye L
Gynecol Endocrinol · 2025 Dec · PMID 40448966 · Publisher ↗
This study investigates the causal associations between interleukin receptor-related factors and the development of endometriosis, as their etiology and pathophysiology remain largely unknown. A two-sample Mendelian rand...
This study investigates the causal associations between interleukin receptor-related factors and the development of endometriosis, as their etiology and pathophysiology remain largely unknown. A two-sample Mendelian randomization (MR) approach was employed to analyze genetic variants associated with interleukin receptor related factors as instrumental variables (IVs). The F-values have to be > 10 to exclude weak instrumental bias. The primary analysis was conducted using the inverse variance weighted (IVW) method, with confirmation using the MR-Egger, weighted median (WM), simple mode, and weighted mode methods. Sensitivity analyses were performed to ensure robustness, including tests for heterogeneity, pleiotropy, and leave-one-out. Multivariable MR (MVMR) analysis was used to assess the direct and mediated effects of immune cells. The results indicated significant causal associations between interleukin receptor factors prot-a-1542 (IL-6Rβ), prot-a-1530 (IL-3Rα), and prot-b-38 (IL-1RL1) and endometriosis. Reverse MR analysis showed that endometriosis did not significantly affect prot-a-1530 or prot-b-38. After adjusting for confounders like body mass index and smoking, these factors retained their significance. Additionally, immune cells(ebi-a-GCST90001951) were found to mediate the relationship between prot-b-38 and endometriosis, with an indirect effect accounting for approximately 6.38% of the total effect. This study provides new insights into endometriosis mechanisms involving specific interleukin receptor factors.
Medical treatment for adenomyosis: long term use of progestins.
Vannuccini S, La Torre F, Toscano F … +6 more , Speciale AR, Giani M, Tureli D, Manzi V, Gallone A, Petraglia F
Gynecol Endocrinol · 2025 Dec · PMID 40424290 · Publisher ↗
BACKGROUND: Adenomyosis is a uterine disorder causing menstruation-related symptoms such as dysmenorrhea, heavy menstrual bleeding (HMB) and dyspareunia. A long-term management of the disease is required. Hormonal drugs...
BACKGROUND: Adenomyosis is a uterine disorder causing menstruation-related symptoms such as dysmenorrhea, heavy menstrual bleeding (HMB) and dyspareunia. A long-term management of the disease is required. Hormonal drugs are the most used, including a variety of progestins, even though few data are available on their long-term use in adenomyosis. OBJECTIVE: To evaluate the long-term efficacy of different progestins, including progestin-only pills (POP), for the management of adenomyosis-related symptoms. METHODS: A total of 140 patients (18-45 years) with adenomyosis were treated with progestins for at least three years. The treatment groups included dienogest (2 mg, = 71), levonorgestrel-releasing intrauterine device (52 mg, = 25), desogestrel (75 mcg, = 20), and drospirenone (4 mg, = 24). Symptoms were assessed using the Visual Analogue Scale (VAS) for pain and the Pictorial Blood Assessment Chart (PBAC) method for bleeding. RESULTS: Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients. However, after the first year 49% of patients required a switch to other treatments due to side effects or contraception need. The levonorgestrel-releasing intrauterine device also effectively managed HMB and pain, with 15% of patients switching treatment due to side effects. Both drospirenone and desogestrel improved HMB and dysmenorrhea, but desogestrel had a higher discontinuation rate due to reduced long-term efficacy. Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response. CONCLUSION: Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes.
A different approach to PCOS: evaluation of spermiogram results in male patients with a family history of PCOS.
Ibanoglu MC, Yildiz AG, Tatar OB … +3 more , Seckin B, Cicek T, Engin-Ustun Y
Gynecol Endocrinol · 2025 Dec · PMID 40418647 · Publisher ↗
OBJECTIVE: The aim of this study was to investigate the possible influence of a family history of PCOS on male reproductive health by comparing the spermiogram parameters of patients diagnosed with a first-degree relativ...
OBJECTIVE: The aim of this study was to investigate the possible influence of a family history of PCOS on male reproductive health by comparing the spermiogram parameters of patients diagnosed with a first-degree relative with PCOS with those of a control group without such a family history. METHODS: This prospective study included 51 male participants aged 19-39 years, 25 of whom had a first-degree relative diagnosed with PCOS, while 26 formed the control group. Semen samples were collected and analyzed according to the World Health Organization (WHO) 2021 guidelines. RESULTS: In this study, the spermiogram results of 51 patients aged between 19 and 39 years with a mean age of 31.50 ± 4.80 years were analyzed. The median sperm concentration (0.6 vs. 11.1 million/ml; = 0.024) was significantly lower in the study group and the median total progressive motile sperm concentration (3.7 vs. 3.0 million/ml; = 0.010) was significantly lower in the control group. Comorbidities were more common in the study group, including hair loss (64%; < 0.001) and gynecomastia (25%; = 0.008). Robust regression analysis revealed that semen concentration was significantly higher in subjects with dyslipidemia (+95.973 million/ml; < 0.001), as was sperm motility (+49.081 units; < 0.001) and TPMSC (+74.028 million/ml; < 0.001). CONCLUSION: Men with family history of PCOS have distinct reproductive and metabolic features, including lower median sperm concentration and higher incidence of alopecia and gynecomastia. Dyslipidemia significantly predicted improved sperm concentration and motility.
Effect of letrozole doses on clinical pregnancy rates in polycystic ovary syndrome: a systematic review and network meta-analysis.
Sun Y, Wang J, Chen G
Gynecol Endocrinol · 2025 Dec · PMID 40418644 · Publisher ↗
Letrozole, an aromatase inhibitor, is commonly used for ovulation induction in patients with polycystic ovary syndrome (PCOS). However, the effect of different doses of letrozole on pregnancy outcomes remains controversi...
Letrozole, an aromatase inhibitor, is commonly used for ovulation induction in patients with polycystic ovary syndrome (PCOS). However, the effect of different doses of letrozole on pregnancy outcomes remains controversial. This systematic review and network meta‑analysis aims to compare the effects of different doses of letrozole on pregnancy outcomes in PCOS patients. A systematic search was performed in databases such as PubMed, WOS, and Wanfang for randomized clinical trials (RCTs) assessing different doses of letrozole in PCOS patients. The primary outcome was pregnancy outcome. A network meta‑analysis was conducted using Stata 17's network package and the 'netmeta' and 'gemtc' packages in R software. A total of 30 RCTs involving 3663 patients were included, comparing 11 intervention strategies. Compared with 2.5 mg letrozole, 5 mg letrozole (OR = 1.99, 95% CI: 1.47-2.68; > 0.05), 7.5 mg letrozole (OR = 1.89, 95% CI: 1.17-3.06; > 0.05), and 7.5 mg letrozole combined with clomiphene (OR = 7.60, 95% CI: 1.33-43.35; > 0.05) all significantly improved pregnancy outcomes. Additionally, compared with 2.5 mg letrozole combined with human gonadotropin (HMG), 5 mg (OR = 1.12), 7.5 mg (OR = 1.19), and 20 mg (OR = 1.72) letrozole combined with HMG showed improvements in pregnancy rates, though the differences were not statistically significant ( > 0.05). The lack of unpublished studies and non‑English publications may have introduced publication bias. Letrozole treatment significantly improves pregnancy outcomes in PCOS patients. Moderate‑dose letrozole is recommended as the most effective strategy for improving pregnancy outcomes. Further clinical studies are required to confirm these findings.
The impact of combined use of probiotics and metformin on metabolic parameters in patients with polycystic ovary syndrome.
Li X, Peng X
Gynecol Endocrinol · 2025 Dec · PMID 40418166 · Publisher ↗
This study amed to investigate the combined use of probiotics and metformin on metabolic parameters in patients with polycystic ovary syndrome (PCOS). 138 patients with PCOS were retrospectively included from January to...
This study amed to investigate the combined use of probiotics and metformin on metabolic parameters in patients with polycystic ovary syndrome (PCOS). 138 patients with PCOS were retrospectively included from January to December 2023 and divided into metformin ( = 70) and probiotics-metformin combination ( = 68) groups based on their clinical treatment regimens. After the three-month intervention, the combination group showed significantly greater improvements compared to the metformin group in high-density lipoprotein cholesterol levels ( < 0.001), insulin levels ( < 0.001), and adiponectin levels ( = 0.033). The combination group also exhibited more significant reductions in weight ( = 0.006), waist circumference ( = 0.037), hip circumference ( = 0.044), and waist-hip ratio ( = 0.031). No significant differences were observed between the groups in changes to other metabolic parameters, hormonal profiles, inflammatory markers, or quality of life assessments ( > 0.05). This retrospective pilot study suggests that the addition of probiotics to metformin therapy may improve HDL levels, insulin sensitivity, anthropometric measurements, and adiponectin levels compared to metformin alone in patients with PCOS.
Correlation between lipid metabolism and endometriosis: a meta-analysis.
Yang X, Xue X, Zhu Y … +1 more , Zhang Z
Gynecol Endocrinol · 2025 Dec · PMID 40343766 · Publisher ↗
To analyze and evaluate the correlation between different lipid metabolism levels and endometriosis. The literatures on lipid metabolism and endometriosis published in databases were searched and collected. The search wa...
To analyze and evaluate the correlation between different lipid metabolism levels and endometriosis. The literatures on lipid metabolism and endometriosis published in databases were searched and collected. The search was conducted up to December 2023. The meta-analysis was conducted using Review Manager 5.4.1 software, with odds ratios (ORs) or standardized mean difference (SMD), confidence intervals (CIs), and heterogeneity (I) being calculated. The literature bias was evaluated by drawing funnel plot. Five hundred and eighty-four literatures were retrieved, and finally, 7 literatures were included in this study. Meta-analysis showed that the level of total cholesterol (TC) in endometriosis groups was higher than control group [SMD = 1.70, 95%CI (0.60-2.80), = 0.003], while triglyceride (TG) [SMD=-0.24, 95%CI (-0.68-0.21), = 0.300], low-density lipoprotein (LDL) [SMD = 0.22, 95%CI (-0.34 - 0.78), = 0.440] and high-density lipoprotein (HDL) [SMD = 0.06, 95%CI (-0.14 - 0.25), = 0.550] was not statistically significant. Sensitivity analysis indicated that the combined effect size results were stable and reliable [SMD = 1.70, 95%CI (0.60-2.80), = 0.030]. Funnel plot results showed publication bias. Patients with endometriosis have abnormal blood lipid level, and higher TC level may be a risk factor for endometriosis. The impact of blood lipid metabolism on endometriosis may provide new insights into the pathogenesis and treatment prognosis of endometriosis.
Sex hormone-binding globulin as a biomarker for metabolic risk in European women with polycystic ovary syndrome.
van Bree BE, van der Heijden DMB, van Golde RJT … +3 more , Brouwers MCGJ, Spaanderman MEA, Valkenburg O
Gynecol Endocrinol · 2025 Dec · PMID 40327586 · Publisher ↗
OBJECTIVE: Sex hormone-binding globulin (SHBG) is suggested to be a biomarker for metabolic disturbances in women with polycystic ovary syndrome (PCOS). Insulin resistance and hyperinsulinemia is common in PCOS patients....
OBJECTIVE: Sex hormone-binding globulin (SHBG) is suggested to be a biomarker for metabolic disturbances in women with polycystic ovary syndrome (PCOS). Insulin resistance and hyperinsulinemia is common in PCOS patients. Low SHBG increases free testosterone levels, which further induces hyperinsulinemia. There is no established cutoff level for SHBG in PCOS patients. The goal of this study is to examine SHBG as a biomarker for metabolic dysregulation in European women with PCOS in relation to hyperandrogenemia. METHODS: Retrospective data was collected from the outpatient clinic for menstrual cycle disorders at Maastricht University Medical Center+. 208 women were included, aged between 18 and 40 years old. During a one-time visit to the clinic, physical examination and vaginal ultrasound evaluation were performed as well as endocrine evaluation performed after overnight fast. The women were diagnosed with PCOS according to the European Society of Human Reproduction and Embryology (ESHRE) 2018 guideline. RESULTS: BMI was inversely associated with SHBG (β -0.598, 95% CI [-0.710 to -0.485]) and waist circumference (β -0.604, [-0.715 to -0.492]), even after correction for HOMA-IR and testosterone. A cutoff level <40 nmol/L was significantly, and unfavorably, associated with all metabolic outcomes. Its AUROC was optimal for waist circumference (sensitivity 0.75, specificity 0.82). CONCLUSIONS: SHBG levels <40 nmol/L are indicative for metabolic dysregulation in European women with PCOS. Waist circumference is an important predictor for SHBG, comparable to BMI. Visceral adiposity might play an important role in the expression of SHBG and etiology of PCOS.
An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman.
Sánchez-Prieto M, Mendoza N, Chedraui P … +5 more , Lugo-Salcedo F, Serra-Ribas A, Aladrén-Pérez S, Bustos-Santafé J, Sánchez-Borrego R
Gynecol Endocrinol · 2025 Dec · PMID 40323284 · Publisher ↗
OBJECTIVE: To evaluate the efficacy and safety of a non-hormonal vaginal moisturizer in alleviating the clinical symptoms of vulvovaginal atrophy (VVA). METHODS: This was an observational, single center, open label study...
OBJECTIVE: To evaluate the efficacy and safety of a non-hormonal vaginal moisturizer in alleviating the clinical symptoms of vulvovaginal atrophy (VVA). METHODS: This was an observational, single center, open label study in which the investigational product was applied to postmenopausal women ( = 36) with VVA symptoms three times per week for a period of 12 weeks. Patient's perception of vaginal discomfort, sexual function improvement assessed with the Female Sexual Function Index (FSFI), quality of life evaluated with the Cervantes-SF scale, and subject's satisfaction with the treatment were evaluated after 4 and 12 weeks of product use. In addition, vaginal health was evaluated with the Vaginal Health Index (VHI) score and the vaginal pH. RESULTS: A statistically significant decrease was observed in the severity of the most bothersome symptoms from moderate at baseline (mean 2.47 ± 0.55) to mild after 4 weeks (mean 1.33 ± 0.58) and 12 weeks (mean 1.32 ± 0.74, < 0.0001). VHI scores significantly improved after 4 and 12 weeks compared to baseline (from 11.70 to 16.36 at 4 weeks and 17.34 at 12 weeks, both < 0.0001). Vaginal pH decreased significantly from a mean pH of 6.27 ± 0.46 at baseline to 5.77 ± 0.59 at 4 weeks and 5.56 ± 0.60 at 12 weeks of treatment ( < 0.0001). Total FSFI scores significantly increased, indicating improvement of sexual function, after 4 and then after 12 weeks of product use (Baseline score 20.16 compared to 24.27 at 4 and 23.94 at 12 weeks, both < 0.0001). Quality of life improved (decrease of total Cervantes-SF scores) after 12 weeks of product use as compared to baseline (Baseline 32.09 vs 26.45, = 0.0004). At 12 weeks, a 97.5% reported overall satisfaction with the product and no adverse events related to the product were reported. CONCLUSION: Through limited size study, the proposed non-hormonal vaginal moisturizer demonstrated being effective and safe for the management of VVA symptoms in postmenopausal women, offering significant improvements in symptom severity, vaginal health, sexual function, and quality of life. There is a need for further research with a larger sample and comparison with other similar products.
Efficacy of first-year GnRHa therapy in girls with idiopathic central precocious puberty diagnosed after age 8: a retrospective study.
Ni MM, Yang ST, Sun JY … +4 more , Wu WW, Li M, Gu W, Ji X
Gynecol Endocrinol · 2025 Dec · PMID 40323240 · Publisher ↗
PURPOSE: This study aimed to evaluate the short-term benefits of GnRHa therapy, with a specific focus on the first year of treatment, in girls diagnosed with idiopathic central precocious puberty (ICPP) after age 8, prov...
PURPOSE: This study aimed to evaluate the short-term benefits of GnRHa therapy, with a specific focus on the first year of treatment, in girls diagnosed with idiopathic central precocious puberty (ICPP) after age 8, providing essential evidence to inform clinical decision-making. METHODS: Ninety-four female patients treated with GnRHa at Jiangsu Children's Medical Center from January 2018 to January 2021 were retrospectively reviewed. Patients were divided into two groups based on the age of treatment initiation: on or before age 8 (Group I) and over age 8 (Group II). Hormonal parameters, bone age (BA)/chronological age (CA) ratio, genital organ volume, predicted adult height (PAH), and body mass index (BMI) were assessed during the treatment period. RESULTS: Treatment with GnRHa in girls with ICPP, whether administered before or after age 8, effectively inhibited puberty, slowed BA maturation, and led to an increase in PAH. Group I exhibited significantly better PAH improvement than Group II, with 50% surpassing a 5 cm increase in PAH compared to 25.9% in Group II. No significant changes in BMI were observed following treatment. CONCLUSIONS: The findings of the study support the knowledge that GnRHa treatment is effective in height gain in girls with precocious puberty, especially if started before the age of 8 years.
GnRH ability to release FSH and LH in women with functional hypothalamic amenorrhea: a retrospective cohort study about women with and without polycystic ovarian morphology.
Hager M, Patsch A, Thieme SL … +3 more , Robin G, Dewailly D, Ott J
Gynecol Endocrinol · 2025 Dec · PMID 40289674 · Publisher ↗
Nearly 50% of women with functional hypothalamic amenorrhea (FHA) reveal polycystic ovarian morphology (PCOM), a known risk factor for ovarian hyperstimulation syndrome. However, gonadotropin releasing hormone-agonist (G...
Nearly 50% of women with functional hypothalamic amenorrhea (FHA) reveal polycystic ovarian morphology (PCOM), a known risk factor for ovarian hyperstimulation syndrome. However, gonadotropin releasing hormone-agonist (GnRH-a) triggers are not recommended in FHA, since an inadequate endogenous surge in luteinizing hormone (LH) is expected. We aimed to challenge this concept and evaluated LH levels after GnRH stimulation in FHA-women with and without PCOM. In a retrospective cohort study, 82 women with FHA, who underwent a GnRH stimulation test, were included. Thirty-five women revealed PCOM (42.7%). Twenty minutes after GnRH stimulation, there was an increase of serum LH levels in FHA-PCOM (median basal: 2.7 mIU/mL, IQR 1.1-4.6 versus median stimulated: 13.5 mIU/mL, IQR 7.8-21.6, 0.001) and in FHA-nonPCOM patients (median basal: 2.5 mIU/mL, IQR 0.5-3.9 versus median stimulated: 5.7 mIU/mL, IQR 2.4-13.9, 0.001). Overall, positive correlations ( 0.001) were found between basal and stimulated LH levels. In FHA-PCOM patients, 42.9% of patients revealed stimulated LH levels >15 mIU/mL, while this was the case in 19.1% of FHA-nonPCOM patients ( 0.034). In women with FHA-PCOM, ovulation induction with a GnRH-a trigger might be feasible. Future research should focus on the prediction of an adequate response to GnRH triggers in the IVF setting.
Studys on the effect of decidual stromal cells and trophoblast cells on cytokine secretion by decidual NK cells.
Liu J, Dong P, Wen X … +3 more , Li J, Wang S, Zhang Q
Gynecol Endocrinol · 2025 Dec · PMID 40289655 · Publisher ↗
Unexplained recurrent pregnant loss (URPL) is associated with immune imbalance at the maternal-fetal interface. Decidual immune cells regulate the response of the maternal immune system to the fetus. However, the effect...
Unexplained recurrent pregnant loss (URPL) is associated with immune imbalance at the maternal-fetal interface. Decidual immune cells regulate the response of the maternal immune system to the fetus. However, the effect of decidual stromal cells (DSCs) and trophoblast cells on cytokine secretion by decidual NK cells remains unclear. In this study, we investigated the influence of JEG-3 cells and DSCs on the secretion of cytokines in dNK cells. Furthermore, we investigated whether or not cytokine secretion was regulated by the mitogen-activated protein kinase (MAPK) signaling pathway at the maternal-fetal interface. Our study showed that the secretions of both IFN-γ and TNF-α in dNK cells in URPL were significantly higher than those in normal pregnancy. In the coculture of JEG-3, DSCs, and dNK cells, IL-10 and IL-4 production increased in dNK cells during normal pregnancy; whereas IFN-γ and TNF-α production increased but IL-10 and IL-4 levels decreased during URPL. Furthermore, pretreatment with P38/MAPK inhibition significantly inhibited the secretion of NK1- and NK2-type cytokines in the coculture of the three types of cells. Our study elucidated the influence of trophoblasts and DSCs on the expression of cytokines in dNK cells in patients with URPL and uncovered a complicated crosstalk through the MAPK signal at the maternal-fetal interface.
Reproductive hormone characteristics of obese Chinese patients with polycystic ovarian syndrome: a meta-analysis.
Chen X, Xiao Z, Cai Y … +1 more , Pan Y
Gynecol Endocrinol · 2025 Dec · PMID 40287875 · Publisher ↗
The aim of this analysis is to assess the effect of obesity on reproductive hormones in Chineses patients with polycystic ovarian syndrome (PCOS). Seven databases were searched. The Newcastle-Ottawa Scale (NOS) assessed...
The aim of this analysis is to assess the effect of obesity on reproductive hormones in Chineses patients with polycystic ovarian syndrome (PCOS). Seven databases were searched. The Newcastle-Ottawa Scale (NOS) assessed the quality of included studies. A meta-analysis was performed using random-effects model. The means and standard deviations of the outcomes were synthesized as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs). A total of 23 studies involving 4554 patients with PCOS were included. No significant differences in follicle-stimulating hormone (FSH) ( = 0.51), estradiol (E2) ( = 0.48), and prolactin (PRL) ( = 0.46) levels were found between obese and nonobese PCOS patients. However, obese PCOS patients had significantly lower levels of luteinizing hormone (LH) ( < 0.00001), LH/FSH ( = 0.001), progesterone (P) ( = 0.009), and anti-mullerian hormone (AMH) ( = 0.001). Conversely, they exhibited significantly higher testosterone (T) ( = 0.001) levels. Obese PCOS patients exhibited lower levels of LH, LH/FSH, P, and AMH, but higher T levels compared to nonobese PCOS patients, and no significant difference were observed in FSH, E2, and PRL levels in PCOS patients with and without obesity.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe